Sdi Limited

SDI.ASX

Health Care

Manufacture and distribution of amalgam and composite restorative materials, other dental materials, and product research and development.

Market Data

Price

$1.355

-0.0%
Market Cap

$161.1M

P/E Ratio

13.9x

EPS

$0.097

Div. Yield

2.51%

52-Week Change

+0.2%

Latest Earnings

Appendix 4D Dcember 2025

27 February 2026

Revenue
$52.93
+2.7% YoY
NPAT
$3.75
-2.0% YoY
EPS
$0.03
Dividend
$0.02

SDI Limited's H1 FY26 results show modest revenue growth of 2.7% to $52.9M, driven by strong Australian and Middle Eastern markets, but normalised NPAT declined 2.0% to $3.75M after adjusting for a $0.5M doubtful debt provision. Gross margins expanded 210 bps to 65.6% on operational efficiencies and favourable FX, though Amalgam sales collapsed 23.1% due to EU regulatory bans and market decline, partially offset by Aesthetics growth. Management guidance remains cautious with major capital investments planned ($26M facility expansion commencing April 2026) and a potential acquisition in advanced discussions. Key points: Gross margin expanded significantly by 210 bps to 65.6% driven by operational efficiencies, product mix shift towards higher-margin Aesthetics, and favourable currency movements; Aesthetics product category shows strong growth of 4.5% in local currency across all regions; 'Stela' Amalgam replacement product positioned for wider aesthetic market penetration; Australian market momentum strong, up 11.9% in local currency with Middle Eastern direct exports driving growth of 10.2% regionally

Recent Announcements

27 Feb 2026 Actual Results Neutral

Appendix 4D Dcember 2025

SDI Limited's H1 FY26 results show modest revenue growth of 2.7% to $52.9M, driven by strong Australian and Middle Eastern markets, but normalised NPAT declined 2.0% to $3.75M after adjusting for a $0.5M doubtful debt provision. Gross margins expanded 210 bps to 65.6% on operational efficiencies and favourable FX, though Amalgam sales collapsed 23.1% due to EU regulatory bans and market decline, partially offset by Aesthetics growth. Management guidance remains cautious with major capital investments planned ($26M facility expansion commencing April 2026) and a potential acquisition in advanced discussions. Key points: Gross margin expanded significantly by 210 bps to 65.6% driven by operational efficiencies, product mix shift towards higher-margin Aesthetics, and favourable currency movements; Aesthetics product category shows strong growth of 4.5% in local currency across all regions; 'Stela' Amalgam replacement product positioned for wider aesthetic market penetration; Australian market momentum strong, up 11.9% in local currency with Middle Eastern direct exports driving growth of 10.2% regionally

Get real-time alerts for SDI

Receive AI-powered earnings summaries and instant notifications when Sdi Limited releases results.

Register Free